Sloan-Kettering Institute

Sloan-Kettering Institute. It is the basic and translational research enterprise of the Memorial Sloan Kettering Cancer Center, one of the world's leading cancer centers. Founded in 1945 through the philanthropy of Alfred P. Sloan Jr. and General Motors inventor Charles F. Kettering, the institute is dedicated exclusively to understanding the fundamental biology of cancer and developing more effective therapies. Its scientists work in close collaboration with clinicians at the adjacent Memorial Hospital to accelerate the translation of laboratory discoveries into clinical applications for patients.

History

The institute was established in 1945 with a founding gift from the Alfred P. Sloan Foundation and Charles F. Kettering, reflecting a post-war optimism in applying scientific research to major diseases. Its creation was part of a broader vision to integrate a dedicated research institute with the clinical care provided by the existing Memorial Hospital for Cancer and Allied Diseases. The first director, Cornelius P. Rhoads, was a prominent pathologist who had previously led the medical division of the United States Army Chemical Corps during World War II. Under early leadership, the institute quickly gained prominence, attracting notable researchers like Peyton Rous, whose work on the Rous sarcoma virus laid foundations for viral oncology. Throughout the latter half of the 20th century, it became a global leader in cancer research, contributing significantly to the development of chemotherapy and the understanding of cancer genetics.

Research programs

Research is organized into interdisciplinary programs that bridge traditional departmental lines. The Cancer Biology and Genetics Program investigates the molecular mechanisms driving tumor initiation and progression, including the roles of oncogenes like RAS and tumor suppressors like p53. The Developmental Biology Program explores the parallels between normal embryonic development and carcinogenesis, focusing on signaling pathways such as Hedgehog and Wnt. The Immunology Program is a world leader in cancer immunology, pioneering work on T cell engineering and immune checkpoint inhibitors like those targeting PD-1. The Molecular Pharmacology Program focuses on drug discovery and understanding mechanisms of drug resistance, while the Structural Biology Program uses techniques like X-ray crystallography and cryo-electron microscopy to visualize cancer-related proteins.

Organizational structure

The institute operates as the research arm of the larger Memorial Sloan Kettering Cancer Center, sharing a campus and integrated leadership with Memorial Hospital. It is led by a Director, a position long held by pioneering scientist Joan Massagué, who also heads the Cancer Biology and Genetics Program. Research is conducted by over 120 laboratory heads and their teams within the thematic programs. The institute maintains a graduate school, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences, which awards PhD degrees. Governance and strategic direction are provided in conjunction with the center's Board of Overseers, and the institute collaborates extensively with other research entities, including The Rockefeller University and Weill Cornell Medicine as part of the Tri-Institutional Research Program.

Notable discoveries and contributions

Scientists have been responsible for numerous landmark advances in oncology. Early work included the first successful chemotherapeutic regimens for testicular cancer and Hodgkin lymphoma by researchers like Paul Marks and colleagues. The institute played a central role in the development of interferon as a cancer therapy. In immunology, James P. Allison conducted foundational research on CTLA-4 that led to the first immune checkpoint inhibitor, for which he shared the Nobel Prize in Physiology or Medicine. Other key contributions include the discovery of the BCR-ABL fusion gene in chronic myelogenous leukemia, the identification of the CDK inhibitor family of cell cycle regulators, and major insights into the metastasis process. Its researchers have also been instrumental in advancing CAR T cell therapy for leukemia and lymphoma.

Facilities and resources

The institute's primary facilities are located on the Upper East Side of Manhattan in New York City, centered around the Morten Building and the Zuckerman Research Center. These state-of-the-art buildings house advanced core facilities, including the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, which conducts large-scale DNA sequencing for precision medicine. Other key resources include the Antitumor Assessment Core, the Molecular Cytology Core, and the Bioinformatics Core. The institute also operates the Memorial Sloan Kettering Cancer Center outpatient facility and maintains collaborative research spaces with partners in the Tri-Institutional Research Program. Its location within the larger cancer center provides direct access to patient samples and clinical data, facilitating translational research.

Category:Cancer research organizations Category:Research institutes in New York City Category:Organizations established in 1945